Answers are grounded in this paper and cite their sources.
Preclinical evaluation demonstrates enhanced bone regeneration in diabetic models, indicating potential for treating complex tissue defects.
Diabetic bone defects heal poorly due to hyperglycemia-induced impairments in osteogenesis and angiogenesis, which may lead to delayed regeneration if left untreated. To address these challenges, we developed a composite 3D-printed poly(lactic-co-glycolic acid)/hydroxyapatite (HA) scaffold functionalized with the orchestrated release of vascular endothelial growth factor-mimetic peptide (QK) and osteogenic growth peptide (OGP). The unique triphasic release profile of the scaffold was engineered to mimic natural bone-healing cascades: (1) the initial rapid release of QK peptides resulting from degradation of the dextran methacrylate coating initiates angiogenesis, thereby addressing the critical vascular deficiency; (2) the subsequent sustained release of OGP stimulates osteoblast differentiation and bone formation; and (3) the prolonged release of Ca 2+ and PO 4 3− from nano-HA particles supports matrix mineralization and structural integrity. This spatiotemporally coordinated delivery system surpasses conventional single-factor approaches by simultaneously addressing the multiple pathological features of diabetic bone abnormalities. In-vitro and in-vivo evaluations validated the sequential release kinetics of the scaffold that effectively couple vascularization and osteogenesis, establishing a regenerative milieu that mitigates diabetes-impaired healing deficiencies. The coordinated actions of these components not only offer an alternate therapeutic strategy for diabetic bone defects but also hold potential for application in other complex tissue-regeneration scenarios requiring coordinated multicellular responses.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.